Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of E6007 in Japanese Patients with Moderate Active Ulcerative Colitis
jRCT2080223382Phase 2Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of milategrast in autoimmune colitis (3 arms), sponsored by EA Pharma Co., Ltd. Primary endpoint: Clinical response rate at week 8 (FAS). Started Dec 2016; status: completed.
02
Drugs
milategrast
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080223382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223382.